A01 Somatic engineering of the mammary gland for the development of novel mouse models of triple negative breast cancer. Stefano Annunziato, NKI, Amsterdam, Netherlands.

A02 Potent synergism between FBXW7 and PI3K signalling in a mouse model of endometrial carcinogenesis. Ileana Cuevas, UT Southwestern Medical Center, Dallas, TX, United States.

A03 Perturbation of proteostasis is lethal in SMARCB1 deficient tumors. Giannicola Genovese, UT MD Anderson Cancer Center, Houston, TX, United States.

A04 Cross-species oncogenomics approach identifies PTPN11 as an oncogene and potential therapeutic target in melanoma. Minjung Kim, Moffitt Cancer Center, Tampa, FL, United States.

A05 Investigating mechanisms of obesity-mediated pancreatic cancer progression. Mandar Muzumdar, Koch Institute at MIT, Cambridge, MA, United States.

A06 Automated, high throughput 3D desorption electrospray ionisation (DESI) mass spectrometry imaging of a xenograft model of glioblastoma. Michael Batey, Waters Corporation, Manchester, United Kingdom.

A07 Speedy-mouse models to study melanomagenesis. Ilah Bok, Moffitt Cancer Center, Tampa, FL, United States.

A08 Fast and efficient generation of conditional ROSA26-based mouse models that recapitulate oncogene activation in T-cell acute lymphoblastic leukemia. Steven Goossens, Ghent University, Ghent, Belgium.

A09 Multiplexed in vivo small molecule screening for immediate drug repositioning reveals novel therapeutic targets in metastatic pancreatic cancer. Barbara Grüner, West German Cancer Center (WTZ) University Hospital Essen, German Cancer Consortium (DKTK/DKFZ), Essen, Germany.

A10 Rapid generation of carcinoma mouse models using in vivo electroporation. Josef Leibold, Memorial Sloan Kettering Cancer Center, New York, NY, United States.


A12 CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. Sheng Rong Ng, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States.

A13, PR02 Capturing the integration of Ras-mutant cells into normal epithelial tissue using live imaging. Cristiana Pineda, Yale University, New Haven, CT, United States.

A14 Engineering novel humanized mouse models of cancer. Ali Roghianian, Massachusetts Institute of Technology (MIT), Cambridge, MA, United States.
A15 Generation of clonal replica tumors to interrogate complexity of human cancer in vivo. Andrea Viale, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A16 Humanized mouse models for evaluation of immunotherapeutic drugs. Wolfgang Walther, ECRC Charité Universitätsmedizin Berlin, Berlin, Germany.

A17 Novel patient-derived xenograft (PDX) models from peritoneal metastasis of colorectal carcinoma for drug testing and biomarker analysis. Wolfgang Walther, ECRC Charité Universitätsmedizin Berlin, Berlin, Germany.

A18 Generation of new conditional Kras-alleles by CRISPR-based genome editing. Maria Paz Zafra, Weill Cornell Medicine, New York, NY, United States.

A19 Phosphorylation results in nuclear translocation of dicer protein that increases metabolism, accelerates aging, and alters tumorigenesis. Neeraj Aryal, MD Anderson Cancer Center, Houston, TX, United States.

A20 Pin1 as a regulator of multiple targets of cell growth in lung cancer. Silvia Boffo, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, United States.


A23 Mdm2 phosphorylation by Akt is critical for modulating cellular responses to oxidative stress. Loretah Chibaya, University of Massachusetts Medical School, Worcester, MA, United States.

A24 Bone marrow hematopoietic adaptation as a sensor of early, pre-invasive, epithelial malignancy. Claudia Chiodoni, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

A25 Intestinal tumorigenesis in APCMin/+ mice was higher after acute relative to fractionated proton radiation: Implications for space radiation-induced colorectal carcinogenesis. Kamal Datta, Georgetown University, Washington, DC, United States.

A26, PR03 The tumor suppressor BAP1 regulates the Hippo pathway in pancreatic ductal adenocarcinoma. Anwesha Dey, Genentech Inc., South San Francisco, CA, United States.


A28 Understanding the role of the tumor suppressor p53 in pancreatic cancer development. Brittany Flowers, Stanford University School of Medicine, Stanford, CA, United States.
A29 Generation of a novel transgenic mouse model with regulatable β-catenin expression to examine importance of activated β-catenin signaling to long-term maintenance of mammary tumor growth. Jennifer Gorman, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.

A30, PR08 Altered nucleolar trafficking of the Blm helicase in the mouse reduces size, increases DNA damage and tumor susceptibility, and facilitates premature aging. Joanna Groden, The Ohio State University College of Medicine, Columbus, OH, United States.

A31 Biallelic Dicer1 loss in endothelial cells drives angiosarcoma development. Jason Hanna, St. Jude Children's Research Hospital, Memphis, TN, United States.

A32 Sall2 transcription factor; a novel regulator of G1-S cyclins. Viviana Hermosilla, Universidad de Concepcion, Concepcion, Chile.

A33 Loss of Id4 initiates PIN-like lesions by maintaining stemness in mice prostate. Dhanushka Hewa Bostanthirige, Clark Atlanta University, Atlanta, GA, United States.

A34 EGF receptor activated Notch signaling contributes to pathogenesis of premalignant gastric lesions. Won Jae Huh, Vanderbilt University Medical Center, Nashville, TN, United States.

A35, PR07 Elucidating mechanisms of p53-deficient breast cancer development via lineage tracing and clonal analysis. Zhe Li, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, United States.

A36 Characterizing the role of Egfr signaling in mediating the exacerbative effect of acute inflammation on tumor development in a mouse model for familial adenomatous polyposis. Wei Li, Vanderbilt University Medical Center, Nashville, TN, United States.

A37 SB insertional mutagenesis identifies new metastasis-promoting tumor suppressor genes in pancreatic cancer. Karen Mann, Moffitt Cancer Center, Tampa, FL, United States.

A38 Twist1-driven fatty pancreas formation facilitates pancreatitis and pancreatic ductal adenocarcinoma progression. Thien Ly Nguyen, University of Mississippi Medical Center, Jackson, MS, United States.

A39 Modeling organelle-specific O-glycosylation in driving liver tumor growth, invasion and metastasis. Anh Tuan Nguyen, Institute of Molecular and Cell Biology, Singapore, Singapore.

A40 Twist1 activation in muscle progenitor cells during development or adulthood causes severe muscle loss reminiscent of human cancer cachexia. Parash Parajuli, University of Mississippi Medical Center, Jackson, MS, United States.

A42, PR04 p120 catenin loss drives pancreatic cancer EMT and metastasis through activation of calcium signaling. Jason Pitaresi, University of Pennsylvania, Philadelphia, PA, United States.
**A43** Loss of *Keap1* promotes KRAS-driven lung cancer and results in genotype specific vulnerabilities. Rodrigo Romero, Koch Institute for Integrative Cancer Research, Cambridge, MA, United States.

**A44** Establishment of patient-derived Hispanic gastric cancer xenografts to test targeted therapeutics. Jean Ruiz-Calderon, UPR Medical Science Campus, San Juan, PR, United States.

**A45** Targeted therapy-induced senescence enhances immune surveillance of KRAS mutant lung cancers. Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

**A46** 3D cultured prostate organoids derived from PTEN-conditional KO mouse models of prostate cancer reveal Class IA PI3Kα drives tumorigenesis and the levels of its lipid products are pH dependent. Barzan Sadiq, University of Cambridge, Cambridge, UK, United Kingdom.

**A47** Reducing actin contraction in E-cadherin inactivated mammary epithelial cells leads to the development of invasive lobular carcinoma. Koen Schipper, Netherlands Cancer institute, Amsterdam, Netherlands.

**A48** Ube2v1 promotes EMT and metastasis by suppression of autophagy. Tong Shen, Soochoo University, Suzhou, China.

**A49** Using IL10−/− mouse model to assess heavy-ion radiation exposure associated colitis and colorectal cancer incidence. Shubhankar Suman, Georgetown University, Washington, DC, United States.

**A50** Nrf2 regulates cellular behaviors and Notch signaling in oral squamous cell carcinoma cells in vivo and in vitro. Zheng Sun, Beijing Stomatological Hospital & School of Stomatology, Capital Medical University, Beijing, China.

**A51** Nicotine induces cervical lymph node metastasis of mouse tongue cancer by regulating Prx1/EMT signalling. Xiaofei Tang, Division of Oral Pathology, Beijing Institute of Dental Research, Capital Medical University, Beijing, China.

**A52** Arid1a exerts context-dependent oncogenic and tumor suppressor functions in liver cancer. Shuyuan Zhang, Children’s Research Institute at UT Southwestern, Dallas, TX, United States.